Continuous renal replacement therapy in critically ill patients

被引:93
|
作者
Ronco, C
Bellomo, R
Ricci, Z
机构
[1] Osped San Bortolo, Div Nefrol, Vicenza, Italy
[2] Austin & Repatriat Med Ctr, Intens Care Unit, Heidelberg, Vic, Australia
关键词
acute renal failure; continuous renal replacement therapy; critically ill patients;
D O I
10.1093/ndt/16.suppl_5.67
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Acute renal failure is an evolving syndrome in which new pathogenetic mechanisms have recently been elucidated. The evolution of the field of haemodialysis has led to a parallel development in the therapeutic approach to patients suffering from this syndrome. In particular, acute renal failure is more frequently seen as part of a more complex syndrome, defined as multiple organ failure. In this clinical setting, patients are almost inevitably confined to intensive care units and sepsis is a frequent underlying mechanism of organ failure. The use of new devices and new machines, together with a better understanding of the underlying mechanisms of solute and water removal, have allowed us to achieve higher levels of efficiency and clinical tolerance during artificial renal replacement therapy. The first objective has been reached by increasing the automation of the extracorporeal circuits and the operational levels of the different techniques; the second has been achieved by means of a new generation of monitoring techniques and new machines equipped with specific interfaces and alarms. This progress has made continuous forms of renal replacement (CRRT) possible and easy to perform without major problems or complications. The most promising and effective options for treating acute renal failure in critically ill patients are today offered by continuous renal replacement therapies. Classic indications, but also alternative non-renal indications, have been proposed for these techniques. The most advanced indication is the multiple organ dysfunction occurring in septic patients. The possible removal of proinflammatory mediators may permit a blockade of the systemic inflammation, a modulation of the altered immune response in these patients, and it may lead to a partial or total restoration of the lost homeostasis.
引用
收藏
页码:67 / 72
页数:6
相关论文
共 50 条
  • [21] Pharmacokinetics of trimethoprim/sulfametrole in critically ill patients on continuous renal replacement therapy
    Welte, Rene
    Beyer, Rudolph
    Hotter, Johannes
    Broeker, Astrid
    Wicha, Sebastian G.
    Gasperetti, Tiziana
    Ranke, Paul
    Zaruba, Marc-Michael
    Lorenz, Ingo
    Eschertzhuber, Stephan
    Stroehle, Mathias
    Bellmann-Weiler, Rosa
    Joannidis, Michael
    Bellmann, Romuald
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2020, 75 (05) : 1237 - 1241
  • [22] Pharmacokinetics of cefepime during continuous renal replacement therapy in critically ill patients
    Malone, RS
    Fish, DN
    Abraham, E
    Teitelbaum, I
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (11) : 3148 - 3155
  • [23] Clearance of meropenem during continuous renal replacement therapy in critically ill patients
    F Thalhammer
    P Schenk
    H Burgmann
    UM Hollenstein
    K Ratheiser
    S Breyer
    [J]. Critical Care, 3 (Suppl 1):
  • [24] Micronutrient deficiencies in critically ill patients receiving continuous renal replacement therapy
    Fah, Megan
    Van Althuis, Laura E.
    Ohnuma, Tetsu
    Winthrop, Hilary M.
    Haines, Krista L.
    Williams, David G. A.
    Krishnamoorthy, Vijay
    Raghunathan, Karthik
    Wischmeyer, Paul E.
    [J]. CLINICAL NUTRITION ESPEN, 2022, 50 : 247 - 254
  • [25] Antimicrobial Treatment in Critically Ill Patients Requiring Continuous Renal Replacement Therapy
    Six, S.
    Gury, E.
    Nseir, S.
    [J]. REANIMATION, 2014, 23 (06): : 629 - 637
  • [26] Pharmacokinetics of meropenem during continuous renal replacement therapy in critically ill patients
    J Solé Violan
    J Ferrer Agüero
    B Sádaba
    S Sancho
    R Zaragoza
    P Luque
    M Nieto
    M López
    F García
    C Hernández
    J Azanza
    [J]. Critical Care, 18 (Suppl 1):
  • [27] The incidence of thrombocytopenia associated with continuous renal replacement therapy in critically ill patients
    Ferreira, Jason A.
    Johnson, Donald W.
    [J]. RENAL FAILURE, 2015, 37 (07) : 1232 - 1236
  • [28] Daptomycin pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy
    Rudiger, Alain
    Rentsch, Katharina
    Maggiorini, Marco
    Corti, Natascia
    [J]. CRITICAL CARE MEDICINE, 2011, 39 (05) : 1243 - 1244
  • [29] Evaluation of Thrombocytopenia in Critically Ill Patients Receiving Continuous Renal Replacement Therapy
    Droege, Christopher A.
    Ernst, Neil E.
    Messinger, Nicholas J.
    Burns, Allison M.
    Mueller, Eric W.
    [J]. ANNALS OF PHARMACOTHERAPY, 2018, 52 (12) : 1204 - 1210
  • [30] The impact of continuous renal replacement therapy on antibiotic pharmacokinetics in critically ill patients
    Fiore, Marco
    Peluso, Lorenzo
    Taccone, Fabio Silvio
    Hites, Maya
    [J]. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2021, 17 (05) : 543 - 554